Trial Profile
A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RACHEL
- Sponsors Roche
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 21 May 2012 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 21 May 2012 Actual patient number changed from 391 to 467 as reported by ClinicalTrials.gov.